Sign Out
Antacids or Mineral Supplements Containing Divalent Cations (eg, Aluminium, Calcium, Magnesium): Pharmacokinetic interaction (decreased risedronate absorption). Administer risedronate at least 30 min before an antacid or mineral supplements containing divalent cations are taken.
Drug Affecting Hepatic Microsomal Enzymes: Risedronate does not induce or inhibit cytochrome P-450 (CYP) isoenzymes and is not metabolized. Pharmacokinetic interaction unlikely.
Nonsteroidal Anti-Inflammatory Agents (NSAIDs): No evidence of increased adverse upper gastrointestinal effects. The levels/effects of risedronate may be decreased by NSAIDs.
Histamine H2 Receptor Antagonists, Proton Pump Inhibitors: No evidence of increased adverse upper gastrointestinal effects.
Phosphate Supplements: Risedronate may increase the levels/effects of phosphate supplements.
Aminoglycosides: The levels/effects of risedronate may be decreased by aminoglycosides.
Continue with Google